Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Brod

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Archives of Neurology|October 28, 1997
Gut response. Therapy with ingested immunomodulatory proteinsS A Brod
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|September 7, 1999
Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT systemS A Brod
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|December 29, 2000
Unregulated inflammation shortens human functional longevityS A Brod
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|August 26, 1998
Hypothesis: multiple sclerosis is a type I interferon deficiency syndromeS A Brod
Journal of Autoimmunity|February 1, 1996
Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitisS A Brod, M Khan
Autoimmunity|January 1, 1994
Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosisS A Brod, M Scott
Neurology|June 1, 1994
Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferonsS A Brod, D K Burns
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1991
Restricted T cell expression of IL-2/IFN-gamma mRNA in human inflammatory diseaseS A Brod, D Benjamin, D A Hafler
Annals of Neurology|January 13, 2000
Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitisS A Brod, J W Lindsey, J S Wolinsky
American Family Physician|September 15, 1996
Multiple sclerosis: clinical presentation, diagnosis and treatmentS A Brod, J W Lindsey, J S Wolinsky
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Archives of Neurology|October 28, 1997
Gut response. Therapy with ingested immunomodulatory proteinsS A Brod
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|September 7, 1999
Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT systemS A Brod
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|December 29, 2000
Unregulated inflammation shortens human functional longevityS A Brod
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|August 26, 1998
Hypothesis: multiple sclerosis is a type I interferon deficiency syndromeS A Brod
Journal of Autoimmunity|February 1, 1996
Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitisS A Brod, M Khan
Autoimmunity|January 1, 1994
Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosisS A Brod, M Scott
Neurology|June 1, 1994
Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferonsS A Brod, D K Burns
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1991
Restricted T cell expression of IL-2/IFN-gamma mRNA in human inflammatory diseaseS A Brod, D Benjamin, D A Hafler
Annals of Neurology|January 13, 2000
Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitisS A Brod, J W Lindsey, J S Wolinsky
American Family Physician|September 15, 1996
Multiple sclerosis: clinical presentation, diagnosis and treatmentS A Brod, J W Lindsey, J S Wolinsky
Pageof 4